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ABSTRACT 1 
Background.  It is becoming increasingly apparent that certain mutations in the Plasmodium 2 
falciparum ‘chloroquine resistance transporter’ (PfCRT) alter the parasite’s susceptibility to 3 
diverse compounds. Here we investigated the interaction of PfCRT with three tricyclic 4 
compounds that have been used to treat malaria (quinacrine (QC) and methylene blue (MB)) 5 
or to study P. falciparum (acridine orange; AO). 6 
Methods.  We measured the antiplasmodial activities of QC, MB, and AO against chloroquine-7 
resistant and chloroquine-sensitive P. falciparum, and determined whether QC and AO affect 8 
the accumulation and activity of chloroquine in these parasites. We also assessed the ability of 9 
mutant (PfCRTDd2) and wild-type (PfCRTD10) variants of the protein to transport QC, MB, and 10 
AO when expressed at the surface of Xenopus laevis oocytes. 11 
Results. Chloroquine-resistance conferring isoforms of PfCRT reduced the sensitivity of the 12 
parasite to QC, MB, and AO. In chloroquine-resistant (but not chloroquine-sensitive) parasites, 13 
AO and QC increased the parasite’s accumulation of, and susceptibility to, chloroquine. All 14 
three compounds were shown to bind to PfCRTDd2, and the transport of QC and MB via this 15 
protein was saturable and inhibited by the chloroquine ‘resistance-reverser’ verapamil. 16 
Conclusions.  Our findings reveal that the PfCRTDd2-mediated transport of tricyclic 17 
antimalarials reduces the parasite’s susceptibility to these drugs. 18 
 19 
Keywords.  Drug resistance; Plasmodium falciparum; tricyclic drug; methylene blue; PfCRT; 20 
fluorescent uptake assay; Xenopus oocytes. 21 
  22 
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INTRODUCTION 23 
 24 
The global campaign to control and eliminate malaria is under serious threat from the 25 
emergence and spread of Plasmodium falciparum parasites that are resistant to the existing 26 
antimalarial drugs [1]. The P. falciparum chloroquine resistance transporter (PfCRT) plays a 27 
significant role in the phenomenon of drug resistance; mutations in this protein confer 28 
resistance to the former ‘wonder drug’ chloroquine (CQ) and also affect the parasite’s 29 
susceptibility to a diverse range of molecules, including many of the drugs that have been – or 30 
are currently – deployed as antimalarials [e.g., [2] and reviewed in [3]]. 31 
PfCRT is located at the membrane of the parasite’s digestive vacuole (DV) [4, 5]. Many 32 
quinoline-related drugs, including CQ and quinine, accumulate within this acidic compartment 33 
(pH 5-5.5) via ‘weak-base trapping’ [6]. Here they exert an antimalarial effect by preventing 34 
the conversion of toxic heme monomers, arising from the parasite’s digestion of host 35 
hemoglobin, into the inert crystal hemozoin [7, 8]. Resistance to CQ and quinine is associated 36 
with a reduction in the accumulation of these drugs in the DV, and several biochemical studies 37 
produced indirect evidence for this being attributable to the efflux of CQ and quinine via 38 
mutant PfCRT [9-12]. A direct demonstration of this activity was achieved when the wild-type 39 
PfCRT (PfCRTD10) and a resistance-conferring isoform of the protein (PfCRTDd2) were 40 
expressed in Xenopus laevis oocytes; PfCRTDd2 was shown to possess significant CQ and 41 
quinine transport activity, whereas PfCRTD10 did not [13-15]. These findings aside, much 42 
remains to be understood about the protein’s ability to recognize and transport diverse 43 
compounds. 44 
Here we investigated interactions of PfCRT with quinacrine (QC), methylene blue (MB), 45 
and acridine orange (AO). All three molecules contain a tricyclic scaffold (Supplementary 46 
Figure 1) and will sequester within the DV due to weak-base trapping or, in the case of the 47 
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cationic MB, via weak-base trapping and/or oxidation of the reduced forms of the drug [16-48 
19]. 49 
AO has been employed as a fluorescent dye for the diagnosis of malaria [20] and as a 50 
probe for estimating the pH of the DV (pHDV) in CQ-sensitive and CQ-resistant parasites [21-51 
23]. The latter studies reported that CQ-resistant strains have a lower pHDV than their CQ-52 
sensitive counterparts (pH 5.21 versus pH 5.64), and that this could account for the 53 
differential accumulation of, and susceptibility to, CQ between these parasites. Alternatively, it 54 
has been suggested that the observed difference in the accumulation of AO may instead be 55 
due to its export from the DV via mutant PfCRT [24]. 56 
 MB was the first synthetic antimalarial drug and QC, which was derived from MB, was 57 
the first synthetic antimalarial to be widely used. Both drugs are thought to inhibit heme 58 
detoxification [17, 18, 25], with the redox-cycling capacity of MB potentially exerting an 59 
additional parasiticidal effect [18, 26]. Although QC was set aside following the introduction of 60 
CQ, structural derivatives of QC have since been deployed (pyronaridine) or are undergoing 61 
development [27, 28] as antimalarials. Interest in MB, which until recently was a largely 62 
overlooked antimalarial, has been greatly revived by studies that have found it to be (1) a 63 
potent gametocytocidal and transmission-blocking agent [29, 30], (2) a potential partner drug 64 
that improves the clinical efficacy of amodiaquine and artesunate-amodiaquine [31, 32], and 65 
(3) a relatively well-tolerated drug [31-33]. 66 
A number of in vitro studies have observed cross-resistance between QC and CQ [34-67 
36] and these observations, along with the finding that QC increases the accumulation of CQ in 68 
CQ-resistant but not CQ-sensitive parasites [37], implicate mutations in PfCRT as a 69 
determinant of the parasite’s susceptibility to QC. The relationship between CQ and MB 70 
susceptibility in CQ-resistant P. falciparum is considerably less clear. Several studies have 71 
reported that CQ resistance (and specifically mutant PfCRT) does not impart cross-resistance 72 
to MB [38-40], whereas others have observed modest but significant positive correlations 73 
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between the half-maximal inhibitory concentrations (IC50s) of CQ and MB in P. falciparum [17, 74 
41, 42]. 75 
We have sought to elucidate the mechanisms underpinning these observations by 76 
ascertaining the nature and strength of the interactions between PfCRT and QC, MB, and AO. 77 
Our findings reveal that CQ resistance-conferring isoforms of PfCRT reduce the parasite’s 78 
susceptibility to tricyclic compounds and that, at least in the cases of QC and MB, this 79 
phenomenon is due to the ability of mutant PfCRT to transport these drugs away from their 80 
main site of action. 81 
 82 
MATERIALS AND METHODS 83 
 84 
Culture of P. falciparum-infected Erythrocytes 85 
The use of human blood in this study was approved by the Australian National University’s 86 
Human Research Ethics Committee. Two CQ-sensitive strains (D10 and 3D7), three CQ-87 
resistant strains (K1, RSA11, and Dd2), and three pfcrt transfectant lines (C2GC03, C4Dd2, and 88 
C67G8; [43]) were cultured and synchronized as described previously [12]. 89 
 90 
P. falciparum Drug Susceptibility and Drug Accumulation 91 
Measurements of parasite proliferation, and of [3H]CQ and [3H]AO in accumulation in 92 
trophozoite-infected erythrocytes, were performed according to the protocols provided in the 93 
Supplementary Materials. 94 
 95 
Drug Transport in Xenopus Oocytes Expressing PfCRT 96 
Oocytes were harvested and prepared using the method described in detail in the 97 
Supplementary Materials. PfCRTDd2 and PfCRTD10 were expressed at the oocyte plasma 98 
membrane using an approach outlined elsewhere [13]. The uptake into oocytes of [3H]CQ, as 99 
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well as that of unlabelled QC, MB, and AO (all of which fluoresce), was measured using the 100 
protocols described in the Supplementary Materials. 101 
 102 
Statistics 103 
Statistical comparisons were made using the Student’s t-test for paired or unpaired samples, 104 
or ANOVA in conjunction with Tukey’s multiple comparisons test. 105 
 106 
RESULTS 107 
 108 
Mutant Forms of PfCRT Decrease the Susceptibility of P. falciparum to QC, MB, and AO 109 
The antiplasmodial activities of QC, MB and AO were evaluated in vitro against erythrocytes 110 
infected with field-derived CQ-sensitive (D10 or 3D7) or CQ-resistant (RSA11, K1, or Dd2) P. 111 
falciparum strains. The D10 and 3D7 strains carry the wild-type version of PfCRT (PfCRTD10), 112 
K1 and Dd2 parasites carry resistance-conferring isoforms of the protein (PfCRTK1 and 113 
PfCRTDd2, respectively), and the PfCRT haplotype carried by RSA11 is currently unknown. CQ 114 
was included as a reference drug and the resulting IC50s are presented in Table 1. QC and MB 115 
displayed potent antiplasmodial activities, with IC50s against 3D7 parasites of approximately 116 
10 and 2.5 nM, respectively. However, these values increased 1.6 to 2-fold when the drugs 117 
were tested against the Dd2 strain. AO was the least active of the test compounds, with IC50s 118 
of ~300 nM against the D10 and 3D7 strains, and these values also increased 1.9 to 2.3-fold in 119 
the CQ-resistant strains. The role of PfCRT in the observed decrease in the sensitivities of the 120 
CQ-resistant strains to QC, MB, and AO was investigated using a set of isogenic transfectant 121 
lines [43], which express the wild-type pfcrt allele (C2GC03) or a mutant pfcrt allele from either 122 
Dd2 (C4Dd2) or the CQ-resistant strain 7G8 (C67G8). Consistent with what was observed for the 123 
field-derived strains, the IC50s determined for QC, MB, AO, and CQ were higher in the CQ-124 
resistant lines (C4Dd2 and C67G8) than in the CQ-sensitive C2GC03 line (Table 1). CQ-resistant 125 
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parasites can be partially re-sensitised to CQ in vitro by verapamil (VP) or chlorpheniramine 126 
(CP) ([44] and Table 1) – a phenomenon we have shown to be attributable to the ability of 127 
these drugs to inhibit CQ transport via mutant PfCRT [13, 14, 45]. In the data presented in 128 
Table 1, the presence of 1 µM VP decreased the QC and MB IC50s in all of the CQ-resistant 129 
strains and lines, and was without effect in their drug-sensitive counterparts. Taken together, 130 
these findings suggested that the decreased sensitivity of CQ-resistant parasites to QC and MB 131 
was due to the interaction of these drugs with mutant isoforms of PfCRT. 132 
VP did not have a significant effect on the activity of AO in any of the parasite types 133 
(Table 1). We therefore explored the interaction between AO and PfCRT further by testing 134 
whether AO, like VP or CP, potentiates the activity of CQ against CQ-resistant parasites. An 135 
initial experiment revealed that the presence of 250 nM AO or 1 µM VP decreased the CQ IC50 136 
in the K1 strain by ~30% and 65%, respectively, whereas no significant change was observed 137 
in the 3D7 strain (Supplementary Table 1). Isobolograms describing the interactions of CQ 138 
with AO, and of VP with AO, against the C2GCO3 and C4Dd2 lines indicated these combinations 139 
are additive in C2GCO3 parasites, whereas interactions suggestive of synergism were observed 140 
in the C4Dd2 line (Figure 1). These results suggested that the antiplasmodial activity of 141 
combinations of AO with CQ or VP is dependent on the pfcrt allele expressed and that AO may 142 
behave as a reverser of CQ resistance. 143 
 144 
QC and AO Increase [3H]CQ Accumulation in CQ-resistant Parasites 145 
The resistance-reversing activity of VP causes an increase in the accumulation of [3H]CQ in 146 
CQ-resistant strains, with no such change occurring in drug-sensitive parasites [44]. To 147 
investigate whether AO enhances the effects of CQ via the same mechanism, [3H]CQ 148 
accumulation was measured in CQ-sensitive and CQ-resistant parasites in the presence or 149 
absence of AO, QC, and VP. We found that AO and QC increased the accumulation of [3H]CQ in 150 
CQ-resistant parasites when present at 100 nM and 1 µM, respectively (Figure 2). By contrast, 151 
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1 μM AO had no effect on [3H]CQ accumulation in the drug-sensitive parasites, whereas 100 152 
nM QC caused a modest decrease in [3H]CQ accumulation. The latter result suggests that QC 153 
reduces the amount of free heme, and therefore CQ-binding sites, within the DV of drug-154 
sensitive parasites, whereas the observed increase in [3H]CQ accumulation in the resistant 155 
line indicates that QC possesses a degree of resistance-reversing activity. Moreover, the 156 
finding that 1 µM AO and 5 µM VP increased the accumulation of [3H]CQ in the C4Dd2 line to 157 
similar extents (Figure 2D) further supported the hypothesis that AO potentiates the activity 158 
of CQ against CQ-resistant parasites by blocking the PfCRT-mediated efflux of CQ from the DV. 159 
 160 
QC, MB, and AO Inhibit the Transport of [3H]CQ via PfCRTDd2 161 
Direct measurements of the abilities of QC, MB, and AO to block CQ transport via PfCRTDd2 162 
were undertaken using the Xenopus oocyte system. In a preliminary assay in which the 163 
tricyclic compounds were each tested at 500 µM, QC and AO caused pronounced reductions in 164 
the PfCRTDd2-mediated transport of CQ, whereas MB caused a modest level of inhibition 165 
(Figure 3A). An analysis of the concentration-dependence of inhibition yielded IC50s of 13.5 ± 166 
0.9 µM, 41.0 ± 5.1 µM, and 1.3 ± 0.2 mM for QC, AO, and MB, respectively (Figures 3B-D). 167 
 168 
QC and MB are Substrates of PfCRTDd2 169 
We further investigated the nature of the interactions of PfCRTDd2 with QC, MB, and AO by 170 
performing direct measurements of transport in the Xenopus oocyte system. We achieved this 171 
by re-purposing the radioisotope influx assay for the detection of fluorescent substrates (see 172 
Supplementary Materials). In all cases, there was a linear relationship between concentration 173 
and fluorescence intensity for QC, MB, and AO (Supplementary Figure 2). It was therefore 174 
possible to use the native fluorescence of these compounds to measure their uptake into 175 
oocytes expressing different forms of PfCRT. 176 
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Oocytes expressing PfCRTDd2 were found to accumulate significantly more QC and MB 177 
than either non-injected oocytes or oocytes expressing PfCRTD10, consistent with PfCRTDd2, 178 
but not PfCRTD10, mediating the transport of these tricyclic drugs (Figures 4A and 5A; P<0.001 179 
at 60 minutes). The uptake of QC and MB via PfCRTDd2 was linear over time for at least 2 hours 180 
(Figures 4B and 5B) and the estimated rates of PfCRTDd2-mediated transport (in picomoles 181 
hour-1 per oocyte) were 7.01 ± 1.34 (QC) and 4.73 ± 0.14 (MB). An analysis of the 182 
concentration-dependence of QC and MB uptake revealed, in both cases, that the component 183 
of transport attributable to PfCRTDd2 was saturable (Figures 4C and 5C). A least squares fit of 184 
the Michaelis-Menten equation to the data (Figures 4D and 5D) yielded apparent Michaelis 185 
constants (Km) of 9.8 ± 1.1 and 123 ± 11.5 µM and maximal velocities (Vmax) of 16.3 ± 0.7 and 186 
202 ± 5 picomoles hour-1 per oocyte for QC and MB, respectively. By comparison, in non-187 
injected oocytes and those expressing PfCRTD10, the rate of QC and MB influx increased in a 188 
roughly linear manner with increasing concentrations of the drug (Figures 4C and 5C). This 189 
finding, together with the observation that these two oocyte types took up QC or MB to 190 
similarly low levels, indicates that this component of accumulation is due to the simple 191 
diffusion of the uncharged drug into the oocyte. 192 
Several known inhibitors of PfCRTDd2 were tested for their effect on QC and MB uptake 193 
in oocytes expressing PfCRTD10 or PfCRTDd2, including VP (250 µM), CQ (750 µM), neurotensin 194 
fragment 8-13 (NT; 250 µM) and, in the case of MB uptake, saquinavir (SQV; 250 µM) – which 195 
is the most potent of the inhibitors tested [46]. None of the test compounds affected the 196 
accumulation of QC or MB in the PfCRTD10-expressing oocytes (Figures 4E and 5E). By 197 
contrast, VP reduced the PfCRTDd2-mediated uptake of QC and MB by 86 ± 1.6 and 65 ± 4 198 
percent, respectively, and SQV caused a 71 ± 3 percent decrease in the transport of MB via 199 
PfCRTDd2 (Figures 4F and 5F). Compared with VP, CQ and NT were less potent inhibitors of QC 200 
transport (71 ± 3 and 48 ± 4 percent decreases, respectively) and caused only modest 201 
reductions in the PfCRTDd2-mediated uptake of MB (30 ± 5 and 33 ± 2 percent decreases, 202 
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respectively). 203 
Attempts to detect the transport of AO (75 or 150 μM) via PfCRT were performed at pH 204 
4.5, 5.0, 5.5, and 6.0, and a second series of experiments also made measurements of [3H]AO 205 
transport over the same pH range. Although several of the assays conducted at pH 5.0 206 
appeared to detect a small increase in AO accumulation in the PfCRTDd2-expressing oocytes, 207 
the signal was not reproduced in the majority of the assays carried out. This suggested that 208 
AO is either not a substrate of PfCRTDd2 or that the protein has a very low capacity for AO 209 
transport, such that – at least in the oocyte system – it is obscured by the rate of uptake via 210 
simple diffusion of the uncharged species (the proportion of AO in the uncharged form is 211 
relatively high, even at pH 5.0; Supplementary Table 2). The first scenario raised the 212 
possibility that PfCRTDd2 (and PfCRT7G8) decreases the parasite’s susceptibility to AO without 213 
mediating the efflux of AO from the DV. We therefore compared the accumulation of [3H]AO 214 
between the C2GC03, C4Dd2, and C67G8 lines and found there to be a modest but significant 215 
decrease in [3H]AO accumulation in the CQ-resistant lines (Figure 6). Consistent with the 216 
observed failure of VP to increase the activity of AO against CQ-resistant parasites, VP did not 217 
produce a PfCRT-dependent increase in the accumulation of [3H]AO (data not shown) and 218 
assays performed with the CQ resistance-reverser CP suggest it may, if anything, cause a small 219 
decrease in [3H]AO accumulation in the CQ-resistant lines (Supplementary Figure 3). 220 
 221 
DISCUSSION 222 
 223 
PfCRT is a significant player in the malaria parasite’s steadily expanding resistance to 224 
antimalarial drugs, yet relatively little is understood about the extent of its substrate-225 
specificity or the pharmacology of its transport activity. In this study, assays conducted with 226 
isogenic transfectant lines, which differ only in the isoform of PfCRT they express, revealed 227 
that CQ resistance-conferring isoforms of PfCRT confer a VP-sensitive decrease in the 228 
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parasite’s susceptibility to the tricyclic drugs QC and MB. Characterization of the interaction 229 
of these drugs with a mutant isoform of PfCRT (PfCRTDd2) in the Xenopus oocyte system 230 
provided a mechanistic explanation for this phenomenon; PfCRTDd2 can efflux QC and MB out 231 
of the parasite’s DV and VP inhibits this transport activity. Our findings are also consistent 232 
with QC and MB exerting their main schizontocidal activity within the DV, where they are 233 
thought to prevent the detoxification of heme and where MB is also likely to disrupt vital 234 
redox processes. 235 
We also found that parasites carrying a mutant isoform of PfCRT accumulated less of 236 
the pH probe AO, and were more resistant to its antiplasmodial activity, than parasites 237 
carrying the wild-type version of PfCRT – but these phenomena were not affected by VP. AO 238 
did, however, behave as a CQ resistance-reverser; it inhibited CQ transport via PfCRTDd2 in the 239 
oocyte system (IC50 of 41 µM) and chemosensitized CQ-resistant parasites to CQ. The simplest 240 
explanation for these observations is that AO binds to mutant PfCRT and is translocated at a 241 
low rate, such that it is not consistently detected above the simple diffusion of uncharged AO 242 
into the oocyte. These findings render AO unsuitable for comparing the pHDV between CQ-243 
sensitive and CQ-resistant parasites, since the efflux of the probe via mutant PfCRT will result 244 
in non-pH-dependent changes in the accumulation of AO. Indeed, no significant difference was 245 
observed between CQ-sensitive and CQ-resistant parasites when the pHDV was measured with 246 
several other pH-sensitive dyes [24]. 247 
Our characterization of the interactions between mutant PfCRT and QC in the oocyte 248 
system revealed QC transport via PfCRTDd2 to be a high-affinity and low-capacity process (e.g., 249 
Km(QC) of 9.8 µM compared with Km(CQ) of 232-245 µM [13, 15]) and QC to be a strong 250 
inhibitor of the PfCRTDd2-mediated transport of CQ (QC is comparable in potency to SQV; IC50s 251 
of 13.5 and 13 µM [46], respectively). These data, which indicate that QC can outcompete CQ 252 
for transport via PfCRTDd2, provide a mechanistic explanation for the ability of QC to increase 253 
[3H]CQ accumulation in CQ-resistant parasites. 254 
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The finding that the parasite’s sensitivity to MB is reduced by the PfCRT-mediated 255 
resistance mechanism is consistent with several studies in which a significant correlation 256 
between MB and CQ susceptibilities was observed in P. falciparum [17, 41, 42], but is at odds 257 
with reports of there being no such relationship [38-40]. The basis for this difference is not 258 
clear, but may relate to differences in the parasite proliferation protocols between labs. For 259 
example, even when the same parasite strains were studied (CQ-sensitive ‘D6’ and CQ-260 
resistant ‘W2’), one group observed modest but significant cross-resistance between CQ and 261 
MB [17] whereas another did not [39]. We found PfCRTDd2 to be a medium-affinity and very 262 
high-capacity transporter of MB (e.g., the Vmax values (in picomoles hour-1 per oocyte) for MB 263 
and CQ are 202 and 61-67 [13, 15], respectively), which may explain, at least in part, why VP 264 
and CP inhibited MB uptake to a much lesser extent than what was observed for QC uptake. 265 
However, it is also worth noting that MB was a very poor inhibitor of CQ uptake (IC50 of 1.3 266 
mM) and vice versa. We recently provided evidence for there being at least two distinct, but 267 
antagonistically-interacting, substrate-binding sites within PfCRTDd2 and proposed this region 268 
of the transporter most likely resembles a cavity with multiple points for substrate 269 
interaction [14]. Hence, the relatively poor ability of MB and CQ to interfere with each other’s 270 
transport could arise from these two drugs binding to largely different sets of attachment 271 
points. Likewise, the inability of VP to decrease the AO IC50 (and of CP to increase [3H]AO 272 
accumulation) in CQ-resistant parasites may be due to there being little or no overlap 273 
between the attachment points occupied by AO and VP (or CP). 274 
The high-capacity transport of MB via mutant PfCRT, and the resulting reduction in the 275 
parasite’s susceptibility to the drug, could have future clinical relevance given the potential of 276 
MB to serve as a potent transmission-blocking agent and its inclusion in two candidate 277 
combination therapies (artesunate-amodiaquine-MB and amodiaquine-MB). It is conceivable 278 
that parasites carrying mutant isoforms of PfCRT will be selected by MB-containing 279 
treatments, forming a population from which high-level resistance could evolve. Whether this 280 
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transpires will depend on a number of parameters (none of which are currently known), such 281 
as the approximate concentration of MB within the DV and the extent to which it can be 282 
lowered by mutant PfCRT, how this fluctuates during the treatment course, and for what 283 
period the level of MB within the DV falls beneath the minimum parasiticidal concentration. 284 
Moreover, these factors are likely to be affected by the co-administration of MB with 285 
amodiaquine, since the latter is suspected to be a substrate of mutant PfCRT [12, 47]. It is also 286 
possible that the gametocytocidal activity of MB could be affected by the PfCRT-mediated 287 
resistance mechanism; although mature gametocytes no longer digest hemoglobin, they 288 
retain both PfCRT as well as vesicles that could be the remnant of, or replacement for, the DV 289 
[48, 49]. 290 
The data presented here have (1) broadened the known substrate range of mutant 291 
PfCRT to include tricyclic compounds and (2) established that the PfCRT-mediated efflux of 292 
QC and MB from the DV decreases the parasite’s sensitivity to these molecules. When taken 293 
together with previous studies [13-15], these results reveal a shared mechanism of resistance 294 
for CQ, quinine, quinidine, QC, and MB. Our work therefore adds further support to the 295 
proposal that PfCRT behaves as a ‘multidrug resistance carrier’ [3, 50] and highlights the 296 
potential for there being an interaction between mutant PfCRT and existing and upcoming 297 
antimalarials with quinoline- and acridine-related structures (e.g., ferroquine and 298 
pyronaridine).  299 
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FIGURE LEGENDS 300 
 301 
Figure 1. Isobolograms describing the interactions of verapamil (VP) with chloroquine (CQ), 302 
acridine orange (AO) with CQ, and VP with AO, against erythrocytes infected with C2GCO3 or 303 
C4Dd2 parasites. The data represent the mean ± SEM from 3 independent experiments 304 
(performed on different days), within which measurements were averaged from 3 replicates. 305 
Where not shown, error bars fall within the symbols. In general, a fractional inhibitory 306 
concentration (FIC) of 1.0 suggests that the effects of the two compounds are additive, a FIC ≤ 307 
0.5 suggests synergism, and a FIC ≥ 4.0 indicates antagonism. The mean FICs for the C2GCO3 308 
line were as follows: VP and CQ combination, 1.04; AO and CQ combination, 1.00; VP and AO 309 
combination, 0.99. None of these FICs appeared different from 1.0, consistent with all three 310 
drug combinations being additive in the CQ-sensitive parasite line. The mean FICs for the 311 
C4Dd2 line were as follows: VP and CQ combination, 0.54; AO and CQ combination, 0.94; VP 312 
and AO combination, 0.84. In all three cases, the mean FICs were below 1.0, but were also 313 
above the accepted threshold for categorizing an interaction as synergistic. This finding 314 
suggests that the drug combinations were slightly synergistic in the CQ-resistant parasite line. 315 
 316 
Figure 2.  Effects of quinacrine (QC), acridine orange (AO), and verapamil (VP) on the 317 
accumulation of radiolabelled chloroquine ([3H]CQ) by erythrocytes infected with mature 318 
trophozoite-stage parasites. Panels A, B, and C show data for CQ-sensitive parasites (C2GCO3, 319 
D10, and 3D7, respectively). Panels D, E, and F show data for CQ-resistant parasites (C4Dd2, 320 
RSA11, and K1, respectively). CQ accumulation is expressed in terms of the fold difference in 321 
the [3H]CQ ‘distribution ratio’, which corresponds to the concentration of [3H]CQ within the 322 
infected cells relative to the concentration in the extracellular medium. In panels A and D, the 323 
data represent the mean + SEM from 6 independent experiments (performed on different 324 
days), within which measurements were averaged from 3 replicates. Panels B, C, E, and F 325 
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show the mean + range/2 of 2 independent experiments (performed on different days), 326 
within which measurements were averaged from 3 replicates. In panel E, the SEM for the 100 327 
nM AO treatment was very small and the error bar is therefore not visible. The asterisks 328 
denote a significant difference in [3H]CQ accumulation between the control treatment and 329 
that measured in the presence of QC, AO, or VP: *, P < 0.05; **, P < 0.01; ***, P < 0.001 330 
(ANOVA). 331 
 332 
Figure 3.  Quinacrine (QC), acridine orange (AO), and methylene blue (MB) inhibit the 333 
transport of radiolabelled chloroquine ([3H]CQ) via the Plasmodium falciparum chloroquine 334 
resistance transporter (PfCRT) in Xenopus laevis oocytes.  A, [3H]CQ uptake into oocytes 335 
expressing the Dd2 isoform of PfCRT (PfCRTDd2; black bars) or the D10 isoform of PfCRT 336 
(PfCRTD10; white bars) in the presence of 500 μM unlabelled CQ, QC, AO, or MB.  B -D, 337 
Concentration-dependent inhibition of the uptake of [3H]CQ into oocytes expressing PfCRTDd2 338 
(black circles) or PfCRTD10 (white circles) by QC, AO, or MB. In all panels, [3H]CQ uptake is 339 
expressed relative to that measured in the PfCRTDd2-expressing oocytes under control 340 
conditions. The data represent the mean ± SEM from 3 to 5 independent experiments 341 
(performed on different days and using oocytes from different frogs), within which 342 
measurements were made from 10 oocytes per treatment. Where not shown, error bars fall 343 
within the symbols. Note that non-injected oocytes and oocytes expressing PfCRTD10 take up 344 
[3H]CQ to similar (low) levels via simple diffusion of the neutral species; this represents the 345 
“background” level of CQ accumulation in oocytes. In panel A, the asterisks denote a 346 
significant difference in [3H]CQ uptake between the control PfCRTDd2 treatment and that 347 
measured in the presence of CQ, QC, AO, or MB: ***, P < 0.001 (ANOVA). Abbreviation: IC50, 348 
half-maximal inhibitory concentration. 349 
 350 
Figure 4.  Quinacrine (QC) transport properties of the Plasmodium falciparum chloroquine 351 
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resistance transporter (PfCRT) in Xenopus laevis oocytes.  A, Oocytes expressing the Dd2 352 
isoform of PfCRT (PfCRTDd2; black circles) showed a marked increase in QC accumulation 353 
relative to non-injected oocytes (black triangles) and to those expressing the D10 isoform of 354 
PfCRT (PfCRTD10; white circles). Rates of QC uptake (picomoles hour−1 per oocyte; n = 3 ± 355 
SEM, estimated from uptake at 60 minutes) were as follows: non-injected, 1.74 ± 0.37; 356 
PfCRTD10, 1.50 ± 0.20; PfCRTDd2, 8.62 ± 1.58.  B, The PfCRTDd2-mediated uptake of QC 357 
(obtained by subtracting the average of the uptake measured in non-injected and PfCRTD10-358 
expressing oocytes from that measured in PfCRTDd2-expressing oocytes) was approximately 359 
linear with time for at least 2 hours. The rate of QC transport via PfCRTDd2, estimated from 360 
uptake at 60 minutes, was 7.01 ± 1.34 picomoles hour−1 per oocyte (n = 3 ± SEM).  C, The 361 
effect of QC concentration on QC uptake by non-injected oocytes (black triangles) and oocytes 362 
expressing PfCRTD10 (white circles) or PfCRTDd2 (black circles). The accumulation of QC by the 363 
control oocytes increased linearly with increasing concentrations of QC, although a second 364 
component – attributable perhaps to the binding of QC to the oocyte surface – may have been 365 
present below 2.5 μM.  D, The concentration-dependence of the PfCRTDd2-mediated transport 366 
of QC (in picomoles hour−1 per oocyte).  E,  Uptake of QC into oocytes expressing PfCRTD10 367 
(white bars) or PfCRTDd2 (black bars) in the presence of 750 μM chloroquine (CQ), 250 μM 368 
verapamil (VP), or 250 μM neurotensin (NT).  F, Inhibition of the PfCRTDd2-mediated 369 
transport of QC by VP, CQ, or NT. The extracellular concentration of QC was 40 μM (panels A 370 
and B), 2.5-40 μM (panels C and D), or 10 μM (panels E and F). In all panels except D, QC 371 
uptake is expressed relative to that measured in the relevant PfCRTDd2 control. The data 372 
represent the mean ± SEM from 3 to 11 independent experiments (performed on different 373 
days and using oocytes from different frogs), within which measurements were made from 12 374 
oocytes per treatment. Where not shown, error bars fall within the symbols. In panels E and F, 375 
the asterisks denote a significant difference in QC uptake between the control PfCRTDd2 376 
treatment and that measured in the presence of VP, CQ, or NT: ***, P < 0.001 (ANOVA). 377 
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Abbreviations: Km, apparent Michaelis constant; Vmax, maximum velocity. 378 
 379 
Figure 5.  Methylene blue (MB) transport properties of the Plasmodium falciparum 380 
chloroquine resistance transporter (PfCRT) in Xenopus laevis oocytes.  A, Oocytes expressing 381 
the Dd2 isoform of PfCRT (PfCRTDd2; black circles) showed a marked increase in MB 382 
accumulation relative to non-injected oocytes (black triangles) and to those expressing the 383 
D10 isoform of PfCRT (PfCRTD10; white circles). Rates of MB uptake (picomoles hour−1 per 384 
oocyte; n = 3 ± SEM, estimated from uptake at 60 minutes) were as follows: non-injected, 1.61 385 
± 0.07; PfCRTD10, 1.59 ± 0.08; PfCRTDd2, 6.33 ± 0.22.  B, The PfCRTDd2-mediated uptake of MB 386 
(obtained by subtracting the average of the uptake measured in non-injected and PfCRTD10-387 
expressing oocytes from that measured in PfCRTDd2-expressing oocytes) was approximately 388 
linear with time for at least 2 hours. The rate of MB transport via PfCRTDd2, estimated from 389 
uptake at 60 minutes, was 4.73 ± 0.14 picomoles hour−1 per oocyte (n = 3 ± SEM).  C, The 390 
effect of MB concentration on MB uptake by non-injected oocytes (black triangles) and 391 
oocytes expressing PfCRTD10 (white circles) or PfCRTDd2 (black circles). The accumulation of 392 
MB by the control oocytes increased linearly with increasing concentrations of MB between 393 
150 μM and 2 mM MB. A second component was observed below 150 μM; this probably 394 
reflects the binding of MB to the oocyte surface.  D, The concentration-dependence of the 395 
PfCRTDd2-mediated transport of MB (in picomoles hour−1 per oocyte).  E,  Uptake of MB into 396 
oocytes expressing PfCRTD10 (white bars) or PfCRTDd2 (black bars) in the presence of 250 μM 397 
saquinavir (SQV), 750 μM chloroquine (CQ), 250 μM verapamil (VP), or 250 μM neurotensin 398 
(NT).  F, Inhibition of the PfCRTDd2-mediated transport of MB by SQV, VP, CQ, or NT. The 399 
extracellular concentration of MB was 75 μM (panels A, B, E and F) or 0.025-2 mM (panels C 400 
and D). In all panels except D, MB uptake is expressed relative to that measured in the 401 
relevant PfCRTDd2 control. The data represent the mean ± SEM from 3 to 5 independent 402 
experiments (performed on different days and using oocytes from different frogs), within 403 
Page 19 of 25 
which measurements were made from 12 oocytes per treatment. Where not shown, error 404 
bars fall within the symbols. In panels E and F, the asterisks denote a significant difference in 405 
MB uptake between the control PfCRTDd2 treatment and that measured in the presence of 406 
SQV, VP, CQ, or NT: **, P < 0.01;  ***, P < 0.001 (ANOVA). Abbreviations: Km, apparent 407 
Michaelis constant; Vmax, maximum velocity. 408 
 409 
Figure 6.  Accumulation of radiolabelled chloroquine ([3H]CQ) or radiolabelled acridine 410 
orange ([3H]AO) by erythrocytes infected with mature trophozoite-stage parasites. The white, 411 
black, and gray bars show data for the C2GCO3, C4Dd2, and C67G8 parasite lines, respectively. The 412 
accumulation of [3H]drug was expressed as a ‘distribution ratio’ (i.e., the concentration of 413 
[3H]drug within the infected cells relative to the concentration in the extracellular medium) 414 
and is shown relative to the ratio measured in the C2GCO3 parasites. Under control conditions, 415 
the distribution ratios for CQ and AO in the C2GCO3 line were 773 ± 95 and 299 ± 31, 416 
respectively. The data represent the mean + SEM of 4 independent experiments (performed 417 
on different days), within which measurements were averaged from 2 replicates. The 418 
asterisks denote a significant difference in [3H]drug accumulation between the C2GCO3 line and 419 
that measured in the C4Dd2 or C67G8 lines: *, P < 0.05; **, P < 0.01; ***, P < 0.001 (ANOVA, with 420 
“experiment” nominated as a “blocking factor”). 421 
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 Table 1.  In Vitro Antiplasmodial Activities of Chloroquine (CQ), Quinacrine (QC), 
Acridine Orange (AO), and Methylene Blue (MB) against CQ-Sensitive and CQ-Resistant 
P. falciparum Parasites 
 IC50 (nM)a 
Strain/ 
lineb 
Chloroquine Quinacrine Acridine orange Methylene blue 
Control + 1 μM VP Control + 1 μM VP Control + 1 μM VP Control + 1 μM VP 
D10 26 ± 2.6 27 ± 2.5 - - 288 ± 20 283 ± 63 - - 
3D7 21 ± 0.5 20 ± 0.6 9.8 ± 0.2 9.9 ± 0.2 309 ± 34 294 ± 24 2.6 ± 0.04 2.5 ± 0.08 
RSA11 354 ± 39c 43 ± 5.5f - - 586 ± 39e 563 ± 84 - - 
K1 255 ± 26c 63 ± 8.4f - - 652 ± 42c 644 ± 98 - - 
Dd2 142 ± 7.2c 26 ± 2.4f 16 ± 1.4d 7.9 ± 0.6f 606 ± 19d 549 ± 30 5.3 ± 0.06c 2.3 ± 0.08f 
C2GC03 8.3 ± 0.4 8.4 ± 0.2 9.9 ± 0.8 10 ± 0.2 373 ± 28 268 ± 42 2.5 ± 0.03 2.1 ± 0.1 
C4Dd2 130 ± 9.7c 47 ± 8.1f 19 ± 0.6c 8.9 ± 1.1f 592 ± 56d 610 ± 27 4.3 ± 0.4c 1.9 ± 0.02f 
C67G8 89 ± 4.1c 24 ± 2.9g 14 ± 0.8d 11 ± 0.2h 491 ± 19 501 ± 20 4.7 ± 0.05c 2.5 ± 0.03f 
Abbreviations: IC50, half-maximal inhibitory concentrations; VP, verapamil. 
aThe IC50s are shown as the mean ± SEM from 3 to 11 independent experiments (performed on 
different days), within which measurements were averaged from 2 or 3 replicates. 
bField-derived CQ-sensitive strains: D10 (Papua New Guinea); 3D7 (Africa). Field-derived CQ-
resistant strains: RSA11 (South Africa); K1 (Thailand); Dd2 (Indochina/Laos). Isogenic pfcrt 
transfectant lines: C2GCO3 (CQ-sensitive); C4Dd2 (CQ-resistant); C67G8 (CQ-resistant). 
P values determined from Student t-test comparisons with the relevant CQ-sensitive strain or line 
(and within the same drug treatment) were less than c0.001, d0.01, or e0.05. 
P values determined from Student t-test comparisons with the control treatment from the same CQ-
sensitive strain or line (and within the same drug treatment) were less than f0.001, g0.01, or h0.05. 
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Supplementary Materials and Methods 
 
Measurements of P. falciparum Drug Susceptibility 
Parasite proliferation was measured in 96-well plates using either the [3H]hypoxanthine 
incorporation method or the lactate dehydrogenase (pLDH) assay. The [3H]hypoxanthine 
incorporation assay was performed over 72 hours using a protocol described elsewhere [1], 
and the starting hematocrit and parasitemia were both approximately 1%. The MalstatTM 
reagent (Flow Inc.) was used to measure pLDH activity in accordance with the method of 
Makler and colleagues [2], and these assays were performed over 48 hours with a starting 
hematocrit and parasitemia of approximately 1% and 2%, respectively. The level of parasite 
proliferation in the presence of each drug concentration was expressed as a percentage of the 
proliferation measured in the absence of drug. The IC50 (i.e., the concentration of drug at 
which the inhibition of parasite growth is half-maximal) was determined in SigmaPlot by a 
least-squares fit of the equation y = a/[1+([drug]/IC50)c] to the data, where y is the percent 
parasite proliferation, a is the maximum change in the percent parasite proliferation, and c is 
a fitted constant. The IC50s obtained using the [3H]hypoxanthine incorporation method were 
indistinguishable from those generated with the pLDH assay. 
Antimalarial drug combinations were assessed using fixed-ratio isobolograms [3] as 
described previously [4]. Fractional inhibitory concentrations (FICs) were calculated for each 
drug within a combination as follows: FIC (A) = the IC50 for drug A in a combination divided 
by the IC50 for drug A alone; FIC (B) = the IC50 for drug B in a combination divided by the IC50 
for drug B alone. The isobolograms were constructed by plotting FIC (A) against FIC (B) for 
each combination.  It is generally accepted that a drug combination is synergistic if the FIC is ≤ 
0.5, antagonistic if the FIC is ≥ 4.0 [5], and additive if the FIC is not significantly different from 
1. 
In all cases, at least three independent experiments were performed (on different 
days), and within each experiment measurements were averaged from three replicates. 
 
P. falciparum Drug Accumulation Assays 
The accumulation of [3H]CQ and [3H]AO was measured in mature trophozoite-infected 
erythrocytes (~36 hours post-invasion). In the experiments giving rise to the data presented 
in Figure 2, hematocrit and parasitaemia were approximately 1% and 5%, respectively, and 
the initial extracellular concentration of [3H]CQ was 2 nM (7 Ci/mmol; Moravek 
Biochemicals). Prior to the addition of [3H]CQ, the cell suspension was incubated for 15 
minutes at 37°C in the presence or absence of the test compound (unlabelled VP, AO, or QC). 
The 1-hour incubation was terminated by the addition of 100 μL of dibutyl phthalate to the 
cell suspension and immediate centrifugation (17000 × g, 1 minute) to sediment the cells. The 
supernatant solution was aspirated and the microcentrifuge tube tip containing the pelleted 
cells was cut off and placed in a scintillation vial (PerkinElmer). The cells were lysed with 100 
μL of Solvable (Packard; 30 minutes at room temperature) and the sample decolourised by 
the addition of 100 μL of hydrogen peroxide (Sigma; 30 minutes at room temperature). 
Scintillation fluid (2 mL of Ultima Gold; PerkinElmer) was added to each vial and the samples 
were shaken overnight. The radioactivity was measured with a Packard Tri-Carb 4640 liquid 
scintillation analyser. The data presented in panels A and D of Figure 2 were derived from 
three independent experiments (performed on different days), within which measurements 
were averaged from three replicates. Panels B, C, E, and F of Figure 2 show the mean of two 
independent experiments (performed on different days), within which measurements were 
averaged from three replicates. 
The experiments giving rise to the data presented in Figure 6 and Supplementary 
Figure 3 were performed according to a protocol described in detail elsewhere [6] with minor 
modifications. Briefly, the hematocrit was 2% and the parasitaemia ranged between 3.2 and 
8.4%, and the initial extracellular concentrations of [3H]CQ (20 Ci/mmol) and [3H]AO (25 
Ci/mmol) (both from American Radiolabeled Chemicals, ARC) were 20 nM and 50 nM, 
respectively. The 1-hour incubation at 37°C was terminated by transferring an aliquot of the 
suspension (200 µL, in duplicate) to a microcentrifuge tube containing 300 µL of dibutyl 
phthalate (Sigma-Aldrich), which was centrifuged immediately (17,000 × g, 2 minutes) to 
sediment the cells. The supernatant solution was removed by aspiration and residual 
radioactivity on the sides of the tube was removed by rinsing four times with water, after 
which the majority of the dibutyl phthalate was aspirated. The cell pellet was dissolved in 1 M 
NaOH (100 μL, 2 hours at 55°C) and the sample decolourised by the addition of 12.5% w/v 
bleach (25 μL, 2 hours at room temperature) prior to dilution with water (1 mL). The sample 
was then transferred to a scintillation vial, mixed with scintillation fluid (1.5 mL of Irga-Safe 
Plus; PerkinElmer), and the radioactivity measured with a PerkinElmer Tri-Carb 2810 liquid 
scintillation analyser. The data presented in Figure 6 were derived from four independent 
experiments (performed on different days), within which measurements were averaged from 
two replicates. 
In all cases, the drug accumulation ratio (i.e., the concentration of [3H]drug within the 
infected cells relative to the concentration in the extracellular medium) was calculated using a 
previous estimate of the water volume of a trophozoite-infected erythrocyte (75 fL) [7]. 
 
Harvest, Preparation and Microinjection of X. laevis Oocytes 
Ethical approval of the work performed with the X. laevis frogs was obtained from the 
Australian National University Animal Experimentation Ethics Committee (Animal Ethics 
Protocol Number A2013/13) in accordance with the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes. Sections of ovary were surgically removed using a 
procedure adapted from the Laboratory Xenopus handbook [8]. Adult female X. laevis frogs 
(purchased from NASCO) were anaesthetised by submersion in a solution of ethyl 3-
aminobenzoate methanesulfonate salt (1.6 g/L of tap water; Sigma-Aldrich) and 1 mM 
NaHCO3 (Sigma-Aldrich). Anaesthesia was complete after approximately 20 minutes, or when 
the frog could be turned onto its back without eliciting a response. The frog was then placed 
onto a container of ice covered with two sheets of moist paper towel. A moist sheet of paper 
towel was also placed over the frog’s head and another over its legs, leaving the abdomen 
exposed. Ice was piled onto the frog’s head and legs to prevent bleeding. After the abdomen 
was swabbed with a cotton bud sprayed with 80% ethanol, a sterile scalpel was used to make 
a 1 cm incision directly above the position of an ovary – first through the skin and then though 
the muscle layer. Sections of the ovary were removed with sterile, surgical-grade tweezers 
and scissors and placed in a pre-weighed petri dish containing ‘calcium-free oocyte ringer’ 
(OR2-) buffer (82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1 mM Na2HPO4, 5 mM HEPES; pH 7.8). 
The incision was closed with one stitch of absorbable suture (B. Braun) in the muscle layer, 
and two stiches of non-absorbable suture (B. Braun) in the skin layer. The wound was 
swabbed with a cotton bud sprayed with 80% ethanol, after which the frog was returned to 
an empty tank. The frog then recovered under a sheet of moist paper towel, and was 
submersed in tap water once fully awake.  
The petri dish was re-weighed and the mass of the ovary calculated. The ovary sections 
were cut into pieces containing around 200 oocytes. If the total mass of the ovary tissue was 
17 g or less, the sections were transferred to a 100 mL Erlenmeyer flask, whereas a 250 mL 
Erlenmeyer flask was used when the total mass was greater than 17 g. The ovary pieces were 
washed with OR2- buffer (five times, or until the buffer was no longer cloudy) before being 
incubated for 16 hours at 16°C on an orbital shaker in OR2- buffer supplemented with 0.5 M 
Na2HPO4 (Sigma-Aldrich), bovine serum albumin (250 mg/mL, Sigma-Aldrich), and 
collagenase D (Roche). The volume of the buffer was 25 mL and 50 mL for the 100 mL and 
250 mL flasks, respectively. The amount of collagenase D added to the solution was described 
by the equation y = 0.44x + 11.5, where x was the mass of ovary tissue in g and y was the mass 
of collagenase in mg. This ratio of collagenase D to ovary mass typically produced good yields 
of healthy, single, and de-folliculated oocytes when the ovary mass ranged from 11 to 24 g. 
The collagenase-treated oocytes were washed ten times with OR2- buffer and five times with 
‘calcium-containing oocyte ringer’ (OR2+) buffer (OR2- buffer supplemented with 1 mM CaCl2 
and 50 μg/mL gentamycin). An ovary mass of 14-20 g usually yielded 2000-5000 healthy, de-
folliculated oocytes of a suitable size and age (developmental stages V and VI) for 
microinjection with cRNA (20 ng per oocyte) encoding PfCRT. The injections were performed 
using a Nanoliter 2000 Injector and Micro4 Controller (World Precision Instruments) with 
fine-tipped glass capillaries that were shaped on a Flaming/Brown micropipette puller (Sutter 
Instrument Co.). Oocytes were stored at 16-18°C in OR2+ buffer (which was replaced daily) 
and the solute uptake experiments were performed 3-6 days post-injection. 
 
Measurements of Drug Transport in Xenopus Oocytes 
The direction of drug transport in the PfCRT oocyte expression system is from the acidic 
extracellular medium (pH 5.0 to 6.0) into the oocyte cytosol (pH 7.2) [9], which corresponds 
to the efflux of drug from the acidic digestive vacuole (pH 5 to 5.5) [10-12] into the parasite 
cytosol (pH 7.3) [13]. A key advantage of this system is that it allows PfCRT to be studied 
directly and in isolation, without confounding effects such as the binding of drugs to heme or 
interactions of the compound with other targets or transporters. 
Unless specified otherwise, the drug influx assays were performed over 1-2 hours at 
27.5°C and in ND96 buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM MES, 
and 10 mM Tris-base). The uptake of [3H]CQ (0.25 μM; 20 Ci/mmol; ARC) was measured at pH 
6.0 and in the presence of 15 μM unlabelled CQ. A subset of experiments attempted to 
measure the transport of [3H]AO (0.2 μM; 25 Ci/mmol; ARC) into oocytes in the presence of 
unlabelled AO (1, 2.5, 5, or 10 μM) at pH 4.5, 5.0, 5.5, and 6.0. For each treatment, 10 oocytes 
were transferred to a 5 mL polystyrene round bottom tube (Falcon) and washed twice with 
3.5 mL of ND96 buffer, with the residual buffer removed by pipette. Influx commenced with 
the addition of 100 µL of ND96 buffer supplemented with [3H]CQ (or [3H]AO), unlabelled CQ 
(or AO) and, where specified, an unlabelled inhibitor (e.g., QC, AO, MB, or VP). The assay was 
terminated by removing the reaction buffer with a pipette and washing the oocytes twice with 
3.5 mL of ice-cold ND96 buffer. Each oocyte was transferred to a separate scintillation vial 
and incubated overnight at room temperature in 200 µL of 10% SDS (Sigma-Aldrich). The 
lysed oocyte was then combined with 1.5 mL of Irga-Safe Plus and the radioactivity measured 
with a PerkinElmer Tri-Carb 2810 liquid scintillation analyser.  
The IC50 values presented in Figures 3B-D were determined in SigmaPlot by a least-
squares fit of the equation y = ymin + [(ymax – ymin)/(1 + ([inhibitor]/IC50)c] to the data, where y 
is PfCRTDd2-mediated CQ transport, ymin and ymax are the minimum and maximum values of y, 
and c is a fitted constant. PfCRTDd2-mediated CQ transport was calculated by subtracting the 
uptake measured in oocytes expressing PfCRTD10 from that in oocytes expressing PfCRTDd2. 
Note that non-injected oocytes and oocytes expressing PfCRTD10 take up [3H]CQ to similar 
(low) levels via simple diffusion of the neutral species; this represents the ‘background’ level 
of CQ accumulation in oocytes (refer to [9] for full data and a detailed discussion). 
The influx of unlabelled QC (10 or 40 μM) and MB (75 μM) was detected using the 
intrinsic fluorescence of these drugs and the uptake assays were performed at pH 6.0 and pH 
5.0, respectively. The composition of the pH 5.0 ND96 buffer was 96 mM NaCl, 2 mM KCl, 1 
mM MgCl2, 1.8 mM CaCl2, and 20 mM homo-PIPES. A subset of experiments attempted to 
measure the transport of unlabelled AO (75 or 150 μM) at pH 4.5, 5.0, 5.5, and 6.0. The 
fluorescence-based experiments were performed as described for the radioisotope uptake 
assays with the following modifications. At the completion of the incubation, the washed 
oocytes were transferred to separate wells of a flat 96-well plate (NUNC or PerkinElmer) that 
had been preloaded with 200 µL of 10% SDS. Each plate included a standard curve that 
consisted of 10 different concentrations of the fluorescent substrate under study, with each 
sample being prepared in a 10% SDS solution containing a lysed oocyte (see Supplementary 
Figure 2). The plates were incubated overnight at room temperature and mixed on an orbital 
shaker the following day for approximately 5 minutes. The fluorescence intensity was 
measured using either a BMG Labtech FLUOstar Optima or a Tecan Infinite M1000 PRO plate-
reader. The excitation and emission wavelengths were as follows: QC, 440 and 510 nm; AO, 
485 and 520 nm; MB, 668 and 682 nm. 
The kinetic parameters for QC and MB transport via PfCRTDd2 (Figures 4D and 5D, 
respectively) were determined in SigmaPlot by a least-squares fit of the Michaelis-Menten 
equation (v = Vmax[substrate]/(Km + [substrate]) to the data. 
In all cases, at least three independent experiments were performed (on different days 
and using oocytes from different frogs), and within each experiment measurements were 
made from 10-12 oocytes per treatment. 
Supplementary Table 1.  In Vitro Antiplasmodial Activity of Chloroquine (CQ) against 
3D7 and K1 P. falciparum Parasites in the Absence or Presence of Acridine Orange (AO) 
or Verapamil (VP). 
 
Strainb 
IC50 (nM)
a 
CQ CQ + 250 nM AO CQ + 1 µM VP 
3D7 17 ± 4 14 ± 5 15 ± 4 
K1 131 ± 11 93 ± 14c 46 ± 10c 
Abbreviations: IC50, half-maximal inhibitory concentration. 
aThe IC50s are shown as the mean ± SEM from 3 independent experiments (performed on 
different days), within which measurements were averaged from 3 replicates.  
b3D7 is a field-derived CQ-sensitive strain from Africa and K1 is a field-derived CQ-
resistant strain from Thailand. 
cA student t-test comparison with the CQ IC50 determined for the K1 strain in the absence 
of AO or VP yielded a P value less than 0.05. 
 
Supplementary Table 2.  Percentages of Chloroquine, Quinacrine, and Acridine Orange 
in their Neutral, Monoprotonated (H+), or Diprotonated (H22+) Forms in Solutions of 
Different pH. 
 
 
  
pH 
CQ QC AO
a
 
% CQ % CQH
+
 % CQH2
2+
 % QC % QCH
+
 % QCH2
2+
 % AO % AOH
+
 
5.0 0.0000005 0.0799997 99.9199998 0.0000005 0.1261314 99.8738681 0.0015849 99.9984151 
5.5 0.0000050 0.2525445 99.7474505 0.0000050 0.3977775 99.6022175 0.0050116 99.9949884 
6.0 0.0000497 0.7942781 99.2056722 0.0000495 1.2471555 98.7527951 0.0158464 99.9841536 
6.4 0.0003100 1.9714568 98.0282332 0.0003065 3.0747290 96.9249645 0.0397949 99.9602051 
6.9 0.0029731 5.9792417 94.0177852 0.0028739 9.1167741 90.8803520 0.1257343 99.8742657 
7.4 0.0263210 16.7393496 83.2343294 0.0240013 24.0772048 75.8987939 0.3965286 99.6034714 
8.4 1.0392882 66.0955322 32.8651795 0.7522247 75.4603423 23.7874330 3.8286504 96.1713496 
The percentages were calculated using the Henderson-Hasselbach equation (pH = pKa + log ([A
-
]
 
/
 
[HA])) using the pKa 
values shown in Supplementary Figure 1. 
Abbreviations: CQ, chloroquine; CQH
+
, monoprotonated chloroquine; CQH2
2+
, diprotonated chloroquine; QC, quinacrine; 
QCH
+
, monoprotonated quinacrine; QCH2
2+
, diprotonated quinacrine; AO, acridine orange; AOH
+
, monoprotonated 
acridine orange.
 
a
Note that the concentration of the neutral form of AO at pH 5.0 is 32-fold greater than that of neutral QC at pH 6.0. 
Supplementary Figure 1.  The structures of the compounds used in this study. Abbreviation: 
pKa, the negative logarithm to the base 10 of the acid dissociation constant (Ka).
 
  
Supplementary Figure 2.  The fluorescence intensities of quinacrine (QC), acridine orange 
(AO), and methylene blue (MB) are linear with concentration in a 10% SDS solution 
containing a lysed oocyte. The drug influx assays entail dissolving each oocyte in 200 µL of a 
10% SDS solution to release the accumulated drug. Given that the resulting oocyte debris 
could reduce the level of excitation energy that reaches the compound and/or absorb the 
emitted fluorescence, it was necessary to prepare each concentration standard in 200 µL of a 
10% SDS solution that contained a lysed oocyte.  A, The fluorescence intensity of QC, which 
was measured at an excitation wavelength of 440 nm and an emission wavelength of 510 nm, 
was linear with concentration between 0.001 and 1 µM.  B, The fluorescence intensity of AO, 
which was measured at an excitation wavelength of 485 nm and an emission wavelength of 
520 nm, was linear with concentration between 0.0625 and 2 µM.  C, The fluorescence 
intensity of MB, which was measured at an excitation wavelength of 668 nm and an emission 
wavelength of 682 nm, was linear with concentration between 0.2 and 100 nM. The data 
represent the mean ± SEM from 3 to 11 independent experiments, performed on different 
days and using oocytes from different frogs. The error bars for each of the data points fell 
within the symbols.
 
Supplementary Figure 3.  The effect of chlorpheniramine (CP) on the accumulation of 
radiolabelled chloroquine ([3H]CQ) or radiolabelled acridine orange ([3H]AO) by erythrocytes 
infected with mature trophozoite-stage parasites. The white, black, and gray bars show data 
for the C2GCO3, C4Dd2, and C67G8 parasite lines, respectively, under control conditions or in the 
presence of 2.5 µM CP. The accumulation of [3H]drug was expressed as a ‘distribution ratio’ 
(i.e., the concentration of [3H]drug within the infected cells relative to the concentration in the 
extracellular medium) and is shown relative to the ratio measured in the C2GCO3 parasites in 
the absence of CP. The data represent the mean + range/2 of 2 independent experiments 
(performed on different days), within which measurements were averaged from 2 replicates. 
 
 
 
 
 
 
 
  
C
Q
C
Q
 +
 2
.5
 µ
M
 C
P
A
O
A
O
 +
 2
.5
 µ
M
 C
P
D
is
tr
ib
u
ti
o
n
 r
a
ti
o
 (
%
 C
2
G
C
0
3
 c
o
n
tr
o
l)
0
20
40
60
80
100
References 
1. Desjardins, R.E., C.J. Canfield, J.D. Haynes, J.D. Chulay. Quantitative assessment of 
antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob 
Agents Chemother 1979; 16:710-8. 
2. Makler, M.T., J.M. Ries, J.A. Williams, et al. Parasite lactate dehydrogenase as an assay 
for Plasmodium falciparum drug sensitivity. Am J Trop Med Hyg 1993; 48:739-41. 
3. Fivelman, Q.L., I.S. Adagu, D.C. Warhurst. Modified fixed-ratio isobologram method for 
studying in vitro interactions between atovaquone and proguanil or 
dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. 
Antimicrob Agents Chemother 2004; 48:4097-102. 
4. van Schalkwyk, D.A., W. Priebe, K.J. Saliba. The inhibitory effect of 2-halo derivatives of 
D-glucose on glycolysis and on the proliferation of the human malaria parasite 
Plasmodium falciparum. J Pharmacol Exp Ther 2008; 327:511-7. 
5. Odds, F.C. Synergy, antagonism, and what the chequerboard puts between them. J 
Antimicrob Chemother 2003; 52:1. 
6. Lehane, A.M., D.A. van Schalkwyk, S.G. Valderramos, D.A. Fidock, K. Kirk. Differential 
drug efflux or accumulation does not explain variation in the chloroquine response of 
Plasmodium falciparum strains expressing the same isoform of mutant PfCRT. 
Antimicrob Agents Chemother 2011; 55:2310-8. 
7. Saliba, K.J., H.A. Horner, K. Kirk. Transport and metabolism of the essential vitamin 
pantothenic acid in human erythrocytes infected with the malaria parasite Plasmodium 
falciparum. J Biol Chem 1998; 273:10190-5. 
8. Green, S.L. The laboratory Xenopus sp. M.A. Suckow ed. 1st ed. Boca Raton: CRC Press, 
2010:136-38. 
9. Martin, R.E., R.V. Marchetti, A.I. Cowan, S.M. Howitt, S. Bröer, K. Kirk. Chloroquine 
transport via the malaria parasite's chloroquine resistance transporter. Science 2009; 
325:1680-2. 
10. Hayward, R., K.J. Saliba, K. Kirk. The pH of the digestive vacuole of Plasmodium 
falciparum is not associated with chloroquine resistance. J Cell Sci 2006; 119:1016-25. 
11. Klonis, N., O. Tan, K. Jackson, D. Goldberg, M. Klemba, L. Tilley. Evaluation of pH during 
cytostomal endocytosis and vacuolar catabolism of haemoglobin in Plasmodium 
falciparum. Biochem J 2007; 407:343-54. 
12. Kuhn, Y., P. Rohrbach, M. Lanzer. Quantitative pH measurements in Plasmodium 
falciparum-infected erythrocytes using pHluorin. Cell Microbiol 2007; 9:1004-13. 
13. Saliba, K.J., K. Kirk. pH regulation in the intracellular malaria parasite, Plasmodium 
falciparum. H+ extrusion via a V-type H+-ATPase. J Biol Chem 1999; 274:33213-9. 
 
